公开(公告)号：US20200038397A1

公开(公告)日：2020-02-06

申请号：US16566473

申请日：2019-09-10

Applicant: KOWA COMPANY, LTD.

Inventor： Yoshio KANEKO ,  Masayuki OHTA

IPC: A61K31/498 ,  A61P27/06 ,  A61K45/00 ,  A61K47/22 ,  A61K31/551

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)−)-1-(4-fluoro-S-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α2 agonist for preventing or treating glaucoma.

公开(公告)号：US20170360782A1

公开(公告)日：2017-12-21

申请号：US15533157

申请日：2015-12-11

Applicant: KOWA COMPANY, LTD.

Inventor： Yoshio KANEKO ,  Masayuki OHTA

IPC: A61K31/498 ,  A61K31/551 ,  A61K45/00 ,  A61K47/22

CPC classification number: A61K31/498 ,  A61K31/551 ,  A61K45/00 ,  A61K47/22 ,  A61P27/06 ,  A61K2300/00

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α2 agonist for preventing or treating glaucoma.

公开(公告)号：US20200297723A1

公开(公告)日：2020-09-24

申请号：US16898920

申请日：2020-06-11

Applicant: KOWA COMPANY, LTD.

Inventor： Yoshio KANEKO ,  Masayuki Ohta

IPC: A61K31/498 ,  A61K45/00 ,  A61K47/22 ,  A61K31/551 ,  A61P27/06

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α2 agonist for preventing or treating glaucoma.